Our study elaborates on these results and now provides evidence from an in vivo set-up demonstrating that the selective P2X3 antagonist A-317491 dose-dependently, though not fully, reversed the increased VMRs to colorectal distension in rats with acute TNBS-colitis. Here, P2RX3 is linked to colitis.